Skip Nav Destination
Issues
1 October 2023
-
Cover Image
Cover Image
The cover image is adapted from Fig. 2 in the article, “Patterns of Evidence-Eased Care for the Diagnosis, Staging, and First-Line Treatment of Breast Cancer by Race–Ethnicity: a SEER-Medicare Study,” by Herbach and colleagues. Racial and ethnic disparities in guideline-recommended breast cancer treatment are well documented, however studies including diagnostic and staging procedures necessary to determine treatment indications are lacking. The purpose of this study was to characterize patterns in delivery of evidence-based services for the diagnosis, clinical workup, and first-line treatment of breast cancer by race–ethnicity. SEER-Medicare data were used to identify women diagnosed with invasive breast cancer between 2000 and 2017, at age 66 or older (n = 215,605). Figure 2 shows the proportions of patients in each race–ethnicity group to receive each component of care for diagnostics and clinical workup. Results showed that Black and American Indian/Alaska Native (AIAN) women had significantly lower rates of evidence-based care across the continuum from diagnostics through first-line treatment compared to non-Hispanic White (NHW) women. AIAN women had the lowest rates of HER2-targeted therapy and hormone therapy initiation. While Black women also had lower initiation of HER2-targeted therapy than NHW, differences in hormone therapy were not observed. The findings suggest patterns along the continuum of care from diagnostic procedures to treatment initiation may differ across race–ethnicity groups. Efforts to improve delivery of guideline-concordant treatment and mitigate racial–ethnic disparities in healthcare and survival should include procedures performed as part of the diagnosis, clinical workup, and staging processes. For more information, see the article beginning on page 1312. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1055-9965
EISSN 1538-7755
Issue Sections
Highlights
Research Articles
Adverse Health Outcomes among Rural and Urban Breast Cancer Survivors: A Population-Based Cohort Study
Alzina Koric; Bayarmaa Mark; Chun-Pin Chang; Shane Lloyd; Mark Dodson; Vikrant G. Deshmukh; Michael Newman; Ankita Date; Lisa H. Gren; Christina A. Porucznik; Benjamin Haaland; N. Lynn Henry; Mia Hashibe
Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
Ji-Qing Chen; Lucas A. Salas; John K. Wiencke; Devin C. Koestler; Annette M. Molinaro; Angeline S. Andrew; John D. Seigne; Margaret R. Karagas; Karl T. Kelsey; Brock C. Christensen
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma
Rikita I. Hatia; Madhulika Eluri; Ernest T. Hawk; Akram Shalaby; Elif Karatas; Ahmed Shalaby; Ahmed Abdelhakeem; Reham Abdel-Wahab; Ping Chang; Asif Rashid; Prasun K. Jalal; Christopher I. Amos; Younghun Han; Tannaz Armaghany; Rachna T. Shroff; Donghui Li; Milind Javle; Manal M. Hassan
New-Onset Diabetes after an Obesity-Related Cancer Diagnosis and Survival Outcomes in the Women's Health Initiative
Prasoona Karra; Sheetal Hardikar; Maci Winn; Garnet L. Anderson; Benjamin Haaland; Benjamin Krick; Cynthia A. Thomson; Aladdin Shadyab; Juhua Luo; Nazmus Saquib; Howard D. Strickler; Rowan Chlebowski; Rhonda S. Arthur; Scott A. Summers; William L. Holland; Thunder Jalili; Mary C. Playdon
Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
En Cheng; Bette J. Caan; Peggy M. Cawthon; William J. Evans; Marc K. Hellerstein; Mahalakshmi Shankaran; Edna Nyangau; Kristin L. Campbell; Catherine Lee; Alexandra M. Binder; Jeffrey A. Meyerhardt; Kathryn H. Schmitz; Elizabeth M. Cespedes Feliciano
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Ronit R. Dalmat; Rebecca A. Ziebell; Aruna Kamineni; Amanda I. Phipps; Noel S. Weiss; Erica S. Breslau; Andrea N. Burnett-Hartman; Douglas A. Corley; V. Paul Doria-Rose; Beverly B. Green; Ethan A. Halm; Theodore R. Levin; Joanne E. Schottinger; Jessica Chubak
A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Katherine Van Loon; Elia J. Mmbaga; Beatrice P. Mushi; Msiba Selekwa; Ally Mwanga; Larry O. Akoko; Julius Mwaiselage; Innocent Mosha; Dianna L. Ng; Wei Wu; Jordyn Silverstein; Gift Mulima; Bongani Kaimila; Satish Gopal; Jeff M. Snell; Stephen Charles Benz; Charles Vaske; Zack Sanborn; Andrew J. Sedgewick; Amie Radenbaugh; Yulia Newton; Eric A. Collisson
Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study
Chaoran Ma; Xiaoyu Wang; James Y. Dai; Constance Turman; Peter Kraft; Konrad H. Stopsack; Massimo Loda; Andreas Pettersson; Lorelei A. Mucci; Janet L. Stanford; Kathryn L. Penney
Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival
Ana Babic; Qiao-Li Wang; Alice A. Lee; Chen Yuan; Nader Rifai; Juhua Luo; Fred K. Tabung; Aladdin H. Shadyab; Jean Wactawski-Wende; Nazmus Saquib; Jihye Kim; Peter Kraft; Howard D. Sesso; Julie E. Buring; Edward L. Giovannucci; JoAnn E. Manson; Meir J. Stampfer; Kimmie Ng; Charles S. Fuchs; Brian M. Wolpin
Null Results in Brief
Associations between Ambient Air Pollutants and Clonal Hematopoiesis of Indeterminate Potential
Claire L. Leiser; Eric A. Whitsel; Alexander Reiner; Stephen S. Rich; Jerome I. Rotter; Kent D. Taylor; Russel P. Tracy; Charles Kooperberg; Albert Vernon Smith; JoAnn E. Manson; Josyf C. Mychaleckyj; Alexander G. Bick; Adam A. Szpiro; Joel D. Kaufman
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.